RESUMO
Plasmapheresis remains the main treatment modality for patients with thrombotic thrombocytopenic purpura. We report a patient who had simultaneous onset of membranoproliferative glomerulonephritis and thrombotic thrombocytopenic purpura. She did not improve after 48 plasmapheresis sessions. A 6-week course of weekly intravenous doses of rituximab was then given. This achieved complete remission of her nephrotic syndrome and improvement in her renal function, so plasmapheresis was ceased. She had a low ADAMTS13 antigen level and a positive ADAMTS13 antibody, both of which reverted to normal after treatment with rituximab. This coincided with a rise in her hepatitis C virus RNA and liver transaminases. Liver biopsies did not reveal active fibrosis. Her hepatitis C virus RNA titre dropped afterwards, and she had no relapses of her thrombotic thrombocytopenic purpura and nephrotic syndrome, for more than 2 years after remission. The simultaneous onset and successful outcomes of both the membranoproliferative glomerulonephritis and thrombotic thrombocytopenic purpura illustrate the usefulness of rituximab. We discuss its use and risks, in the context of chronic hepatitis C infection.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Glomerulonefrite Membranoproliferativa/tratamento farmacológico , Glomerulonefrite Membranoproliferativa/epidemiologia , Hepatite C/epidemiologia , Púrpura Trombocitopênica Trombótica/tratamento farmacológico , Púrpura Trombocitopênica Trombótica/epidemiologia , Proteínas ADAM/sangue , Proteína ADAMTS13 , Adulto , Alanina Transaminase/sangue , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais Murinos , Artérias/patologia , Comorbidade , Creatinina/sangue , Feminino , Glomerulonefrite Membranoproliferativa/patologia , Hepacivirus/genética , Humanos , Fatores Imunológicos/administração & dosagem , Fatores Imunológicos/uso terapêutico , Glomérulos Renais/patologia , Fígado/patologia , Plasmaferese , Púrpura Trombocitopênica Trombótica/terapia , RNA Viral/sangue , Rituximab , Falha de TratamentoRESUMO
Dementia is a common medical problem that affects elderly patients. We report on a 77-year-old man with an intracranial dural arteriovenous fistula who presented with dementia that was initially thought to be irreversible and degenerative. Subsequent neuroendovascular intervention resulted in significant functional and cognitive improvement.
Assuntos
Fístula Arteriovenosa/diagnóstico , Demência/etiologia , Dura-Máter/irrigação sanguínea , Artérias Meníngeas/anormalidades , Idoso , Fístula Arteriovenosa/terapia , Embolização Terapêutica , Humanos , Trombose Intracraniana/diagnóstico , Trombose Intracraniana/terapia , Imageamento por Ressonância Magnética , MasculinoRESUMO
Through the application of advanced technologies and mission concepts, architectures for missions beyond Earth orbit have been dramatically simplified. These concepts enable a stepping stone approach to science driven; technology enabled human and robotic exploration. Numbers and masses of vehicles required are greatly reduced, yet the pursuit of a broader range of science objectives is enabled. The scope of human missions considered range from the assembly and maintenance of large aperture telescopes for emplacement at the Sun-Earth libration point L2, to human missions to asteroids, the moon and Mars. The vehicle designs are developed for proof of concept, to validate mission approaches and understand the value of new technologies. The stepping stone approach employs an incremental buildup of capabilities, which allows for future decision points on exploration objectives. It enables testing of technologies to achieve greater reliability and understanding of costs for the next steps in exploration.
Assuntos
Voo Espacial/tendências , Astronave/instrumentação , Tecnologia , United States National Aeronautics and Space Administration/tendências , Ausência de Peso , Astronomia/instrumentação , Desenho de Equipamento , Exobiologia , Meio Ambiente Extraterreno , Humanos , Marte , Lua , Robótica , Voo Espacial/instrumentação , Estados UnidosRESUMO
Forty children with hypertension between the age of 2 months and 15 years received 0.07 to 0.14 mg/kg of enalapril as a single daily dose. Enalapril was administered orally as a novel extemporaneous suspension in children younger than 6 years of age and as tablets in older children. First-dose and steady-state pharmacokinetics were estimated in children ages 1 to 24 months, 25 months to < 6 years, 6 to < 12 years, and 12 to < 16 years. Maximum serum concentrations for enalapril occurred approximately 1 hour after administration. Serum concentrations of enalaprilat, the active metabolite of enalapril, peaked between 4 and 6 hours after the first dose and 3 and 4 hours after multiple doses. The area under the concentration versus time curve (AUC), adjusted for body surface area, did not differ between age groups. Based on comparison of first-dose and steady-state AUCs, the accumulation of enalaprilat in children ranged from 1.13- to 1.45-fold. For children ages 2 to 15 years, mean urinary recovery of total enalaprilat ranged from 58.3% in children ages 6 to < 12 years to 71.4% in children ages 12 to < 16 years. Urinary recovery for children ages 2 to < 6 years was 66.8%. The mean percentage conversion of enalapril to enalaprilat ranged from 64.7% for children ages 1 to 24 months to 74.6% for children ages 6 to < 12 years. The median effective half-life for accumulation ranged from 14.6 hours in children ages 12 to < 16 years to 16.3 hours in children ages 6 to < 12 years. There were two serious adverse events, neither of which was attributed to enalapril or resulted in discontinuation of the study drug. The extemporaneous suspension used in this study was tolerated well. The pharmacokinetics of enalapril and enalaprilat in hypertensive children ages 2 months to 15 years with normal renal function appears to be similar to that previously observed in healthy adults.
Assuntos
Anti-Hipertensivos/farmacocinética , Enalapril/farmacocinética , Hipertensão/sangue , Adolescente , Análise de Variância , Anti-Hipertensivos/sangue , Anti-Hipertensivos/urina , Área Sob a Curva , Criança , Pré-Escolar , Intervalos de Confiança , Enalapril/sangue , Enalapril/urina , Enalaprilato/sangue , Enalaprilato/urina , Feminino , Humanos , Hipertensão/urina , Lactente , MasculinoRESUMO
I, 3-(2-phenethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene-c arboxamidomethylpyridinyl)-pyrazinone dihydrochloride monohydrate, is a potent, orally active thrombin inhibitor. The compound also has two metabolites which have been shown to have thrombin inhibitory activity: benzylic alcohol M3 metabolite (II) and hydroxymethylpyrazinone M7 metabolite (III). A liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the simultaneous determination of I and its two metabolites in human plasma has successfully been developed. The method consists of treating 0.5 ml plasma with 2 N NaOH and extracting I, II, III and internal standard (IV) with ethyl acetate:methyl-t-butyl ether (1:3, v/v). The analytes were then back-extracted into 2% formic acid. The analytes were chromatographed by high performance liquid chromatography (HPLC) and detected by MS/MS. Positive ionization was used on a heated nebulizer probe monitoring precursor --> product ion combinations in multiple reaction monitoring mode. The linear range is 0.5-1000 nM for I and III and 0.75-1000 nM for II. Recoveries were 88, 74, 78 and 102.1% for I, II and III and the internal standard, respectively in human plasma. Intraday variation using this method was < or = 7.9% for I, < or = 9.0%, for II and < or = 9.5% for III across the standard curve range. This method exhibits good linearity and reproducibility for the three analytes.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Pirazinas/sangue , Piridinas/sangue , Trombina/antagonistas & inibidores , Humanos , Espectrometria de Massas/métodos , Padrões de Referência , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeAssuntos
Lidocaína/farmacocinética , Lipectomia/efeitos adversos , Leite Humano/química , Adulto , Aleitamento Materno , Feminino , Humanos , LactenteRESUMO
The Food and Drug Administration (FDA) issued a second-draft guidance in August 1999 on the subject of in vivo bioequivalence, which is based on the concepts of individual and population bioequivalence (IBE and PBE, respectively). The intention of this guidance is to replace the 1992 guidance that requires that in vivo bioequivalence be demonstrated by average bioequivalence (ABE). Although the concepts of population and individual bioequivalence are intuitively reasonable, a detailed review of the literature has not uncovered clinical evidence to justify the additional burden to the innovator and generic companies as well as the consumer that the new guidelines would impose. The criteria for bioequivalence described in the draft guidance employ aggregate statistics that combine information about differences in bioavailability between formulation means and differences in bioavailability variation of formulations between and within subjects. The purely technical aspects of the statistical approach are reasonably sound. However, PhRMA believes that important operational issues remain that need to be resolved before any changes to current practice are implemented. PhRMA believes that the ideals of prescribability and switchability are intuitively reasonable, but it is uncertain of the extent to which the proposed guidance can achieve these goals. It is not clear whether the attainment of such goals is necessary in the evaluation of bioequivalence given the role this plays in drug development, and the lack of clinical evidence argues against a pressing need to change current practice. PhRMA is concerned that the trade-off offered by the aggregate criteria may ultimately represent more harm than good to the public interest. PhRMA recommends more rigorous evaluation of methods based on two-way crossover designs before moving to methods that require more complex designs. One such method is identified herein and contains procedures for estimating prescribability and switchability. The possibility of a phase-in or trial period to collect replicate crossover data to further evaluate IBE and PBE and possibly allow market access based on these criteria as they are being evaluated has been proposed. PhRMA believes this is unprecedented and will offer little additional information beyond that which can be obtained by simulation or has already been collected by the FDA. Simulation studies have the advantage of allowing evaluation of the sensitivity of various procedures to represent the data patterns as created within the simulation. Operating characteristics by which proposed criteria can be adequately judged have not yet been defined. The limitations of ABE for highly variable drugs and narrow therapeutic drugs are well appreciated and may be addressed by means other than a wholesale change in the current criteria.
Assuntos
Equivalência Terapêutica , Humanos , Estados Unidos , United States Food and Drug AdministrationRESUMO
An LC-MS-MS method and an HPLC-UV method have been developed for the assay of a novel thrombin inhibitor in human fluids. The LC-MS-MS method is developed for plasma, which usually requires maximum sensitivity. The HPLC-UV method is for urine. In both methods, analytes are extracted using liquid-liquid extraction, and analyzed by reversed-phase high-performance liquid chromatography. A tandem mass spectrometer in the multiple reaction monitoring (MRM) mode is used for detection of the analytes in the plasma method. UV is the detector for the urine method. The plasma method has a lower limit of quantitation (LOQ) of 0.1 ng/ml with a linearity range of 0.1-100 ng/ml. The urine method has an LOQ of 8.12 ng/ml (20 nM) and the linear dynamic range is 8.12-8120 ng/ml (20-20000 nM). Both methods are fast, specific and sensitive. Various validation procedures have proven that both methods are rugged, robust and reproducible. The research also suggested that, while LC-MS-MS provides superior sensitivity and selectivity for the determination of drugs and their metabolites at very low concentrations, HPLC with a conventional detector such as UV is still useful in the analysis when the sensitivity requirement is not crucial.
Assuntos
Cromatografia Líquida/métodos , Espectrometria de Massas/métodos , Pirazinas/sangue , Pirazinas/urina , Piridinas/sangue , Piridinas/urina , Trombina/antagonistas & inibidores , Humanos , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , SolventesRESUMO
The angiotensin-converting enzyme (ACE) inhibitor enalapril is commonly used to treat pediatric hypertension. Because some children are unable to swallow tablets or require doses less than the lowest available enalapril tablet, an enalapril suspension was developed. This study examined the relative bioavailability of enalapril suspension (10 mg) (S) compared with 10-mg marketed VASOTEC tablets (T) in 16 healthy adult subjects. The geometric mean ratio (S/T) estimate of urinary recovery of free enalaprilat, the active moiety, was 0.92 (90% confidence interval (CI): 0.80, 1.07). Urinary recovery data indicate that approximately 50% of the dose was absorbed (50% recovered in urine as enalapril plus enalaprilat) with about 30% of the dose recovered as free enalaprilat for both S and T. The geometric mean ratios (S/T) of serum AUC and C(max) were 1.01 (90% CI: 0.90, 1.13) and 0.98 (90% CI: 0.83, 1.16), respectively. Suspension T(max) was slightly shorter (0.5 h) than that for tablet, but this difference is not clinically significant. Both formulations were well tolerated and there were no clinically significant adverse experiences. We conclude that the bioavailability of enalapril oral suspension 10-mg is similar to that of VASOTEC 10-mg tablet. Instructions for compounding enalapril are provided.
Assuntos
Inibidores da Enzima Conversora de Angiotensina/farmacocinética , Enalapril/farmacocinética , Administração Oral , Adolescente , Adulto , Área Sob a Curva , Estudos Cross-Over , Enalapril/administração & dosagem , Feminino , Humanos , Masculino , SuspensõesRESUMO
OBJECTIVE: Losartan was given to subjects with known phenotypes of the polymorphic enzymes CYP2D6 and CYP2C19 to study any possible influence on the metabolism of the drug. METHODS: Plasma concentrations of losartan and E-3174 were studied after oral intake of 50 mg losartan in 24 healthy, male, Swedish Caucasian subjects who were extensive or poor metabolizers (EM/PM) of debrisoquine [cytochrome P450 2D6 (CYP2D6)] or mephenytoin [cytochrome P450 2C19 (CYP2C19)]. RESULTS: The areas under the curve (AUCinfinity) of losartan and E-3174 did not differ between poor and extensive metabolizers of debrisoquine or mephenytoin, respectively. CONCLUSION: About 14% of the antihypertensive drug losartan is metabolized to the active carboxylic acid metabolite E-3174, which contributes to the effect of losartan. The present study suggests that CYP2D6 and CYP2C19 are not involved to any major extent in the in vivo conversion of losartan to E-3174.
Assuntos
Anti-Hipertensivos/farmacocinética , Hidrocarboneto de Aril Hidroxilases , Citocromo P-450 CYP2D6/metabolismo , Sistema Enzimático do Citocromo P-450/metabolismo , Debrisoquina/metabolismo , Losartan/farmacocinética , Mefenitoína/metabolismo , Oxigenases de Função Mista/metabolismo , Polimorfismo Genético , Adulto , Anti-Hipertensivos/administração & dosagem , Anti-Hipertensivos/metabolismo , Citocromo P-450 CYP2C19 , Humanos , Losartan/administração & dosagem , Losartan/metabolismo , MasculinoAssuntos
Antiarrítmicos/metabolismo , Anti-Hipertensivos/metabolismo , Hidrocarboneto de Aril Hidroxilases , Sistema Enzimático do Citocromo P-450/genética , Imidazóis/metabolismo , Losartan/metabolismo , Oxigenases de Função Mista/genética , Esteroide 16-alfa-Hidroxilase , Esteroide Hidroxilases/genética , Tetrazóis/metabolismo , Adulto , Alelos , Citocromo P-450 CYP3A , Genótipo , Humanos , Masculino , Fenótipo , Valores de Referência , VoluntáriosRESUMO
BACKGROUND: Tirofiban, an intravenous glycoprotein IIb/IIIa antagonist, and enoxaparin, a low molecular weight heparin, have each been shown to be effective at reducing cardiac ischemic events compared to unfractionated heparin alone in separate trials of patients with unstable angina and non-Q-wave myocardial infarction. The combination of these agents may offer further therapeutic benefit. MATERIALS AND METHODS: Fifty-five patients with non-Q-wave myocardial infarction were randomized to receive double-blind treatment with tirofiban (0.1 microgram/kg/min i.v.) for 48-108 h coadministered with either enoxaparin (1 mg/kg sc q 12 h) (n=26) or unfractionated heparin (i.v. adjusted to activated partial-thromboplastin time) (n=27) to evaluate pharmacokinetics, pharmacodynamics, and safety. The primary objective of the study was to investigate the effect of unfractionated heparin versus enoxaparin on the plasma clearance of tirofiban. RESULTS: Coadministration of tirofiban and enoxaparin was generally well tolerated. Plasma clearance of tirofiban was 176.7+/-59.8 and 187.5+/-81.8 ml/min, respectively, for enoxaparin and unfractionated heparin-treated patients (P=NS). The mean difference was well within the prespecified criterion for comparability. Administration of tirofiban with enoxaparin vs. unfractionated heparin resulted in lesser variability and a trend towards greater inhibition of platelet aggregation using 5 microM adenosine phosphate agonist. More patients achieved target inhibition of platelet aggregation >70% in the tirofiban and enoxaparin group (84% vs. 65%, P=0.19). Median bleeding time was 21 min for tirofiban and enoxaparin vs. > or =30 min for tirofiban and unfractionated heparin (P=NS). For a given level of inhibition of platelet aggregation, bleeding time was less prolonged with tirofiban and enoxaparin than tirofiban and unfractionated heparin (adjusted mean bleeding time 19.6 vs. 24.9 min, P=0.02). Tirofiban plasma concentration and clearance were comparable whether coadministered with enoxaparin or unfractionated heparin. There were no major or minor bleeding events in either group by the TIMI criteria. INTERPRETATION: The more consistent inhibition of platelet aggregation and lower adjusted bleeding time of tirofiban and enoxaparin vs. tirofiban and unfractionated heparin support the therapeutic potential of combining these two agents. These data from the first clinical report of coadministration of a glycoprotein IIb/IIIa receptor antagonist and a low molecular weight heparin are consistent with prior data which show differential pharmacodynamic effects of enoxaparin and unfractionated heparin on platelet aggregation.
Assuntos
Angina Instável/tratamento farmacológico , Enoxaparina/uso terapêutico , Fibrinolíticos/uso terapêutico , Infarto do Miocárdio/tratamento farmacológico , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/antagonistas & inibidores , Tirosina/análogos & derivados , Angina Instável/sangue , Angina Instável/diagnóstico por imagem , Angiografia Coronária , Método Duplo-Cego , Quimioterapia Combinada , Eletrocardiografia , Enoxaparina/administração & dosagem , Fibrinolíticos/administração & dosagem , Heparina/administração & dosagem , Heparina/uso terapêutico , Humanos , Injeções Intravenosas , Infarto do Miocárdio/sangue , Infarto do Miocárdio/diagnóstico por imagem , Segurança , Síndrome , Tirofibana , Resultado do Tratamento , Tirosina/administração & dosagem , Tirosina/uso terapêuticoRESUMO
Aging in the midface area is seen with ptosis of the malar tissues, hollowing of the infraorbital area, deepening of the nasolabial and mandibular labial folds, and increased jowling. Some of these aging changes are usually not corrected by a standard SMAS face lift. An endoscope-dependent technique was created specifically to address the midface area. The midface tissues are elevated and released in a subperiosteal manner and then suspended to a higher position after endoscopic dissection of the temporal area. The tissues are repositioned to a higher position on the malar area with softening of the nasolabial fold, decreased jowls, and recreation of the desired youthful fullness in the malar and infraorbital area. This procedure can be combined easily with other facial procedures such as rhytidectomy, neck lift, temple lift, and laser resurfacing when indicated. More than 200 procedures have been completed in the last 22 months. This report presents the surgical technique with early follow-up results.
Assuntos
Endoscopia/métodos , Ritidoplastia/métodos , Face/anatomia & histologia , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
The pharmacokinetics of a selective AT1-subtype, nonpeptide, orally active, angiotensin II receptor antagonist, losartan, were characterized in 11 patients with heart failure (New York Heart Association class II, n = 6; class III, n = 4; class IV, n = 1) after oral and intravenous administration. In these patients, average plasma clearance of losartan was 566 mL/min, volume of distribution at steady-state was 34 L, and terminal plasma half-life was 1.5 hours. Average bioavailability was 36%. No clinically significant accumulation of losartan or its active metabolite, EXP3174, occurred after multiple-dose oral administration for 7 to 8 days. Terminal plasma half-life of EXP3174 after oral administration of losartan was 7.6 hours. The pharmacokinetics of losartan in patients in this study appear to be similar to those in healthy subjects studied previously.
Assuntos
Anti-Hipertensivos/farmacocinética , Insuficiência Cardíaca/metabolismo , Losartan/farmacocinética , Administração Oral , Adulto , Anti-Hipertensivos/administração & dosagem , Anti-Hipertensivos/sangue , Estudos Cross-Over , Feminino , Meia-Vida , Humanos , Infusões Intravenosas , Losartan/administração & dosagem , Losartan/sangue , Masculino , Pessoa de Meia-IdadeRESUMO
PURPOSE: To describe two cases involving patients with ruptured globes in whom retrobulbar anesthesia was used successfully. METHOD: A modified retrobulbar anesthesia technique was used to repair two ruptured globes in two patients in whom general anesthesia was contraindicated. RESULT: Using a modified technique, retrobulbar anesthesia did not cause wound gape or prolapse of intraocular contents. CONCLUSIONS: Most open globes should be repaired after administration of general anesthesia. Modified retrobulbar anesthesia can provide a reasonable alternative in rare situations in which general anesthesia subjects the patient to an unacceptable risk.
Assuntos
Anestesia Local/métodos , Lesões da Córnea , Traumatismos Oculares/cirurgia , Órbita/lesões , Esclera/lesões , Adulto , Anestesia Geral , Extração de Catarata , Contraindicações , Feminino , Humanos , Doenças da Íris/etiologia , Doenças da Íris/cirurgia , Implante de Lente Intraocular , Masculino , Pessoa de Meia-Idade , Prolapso , Ruptura , Deiscência da Ferida Operatória/etiologia , Deiscência da Ferida Operatória/cirurgiaAssuntos
Antagonistas de Receptores de Angiotensina , Anti-Hipertensivos/análise , Compostos de Bifenilo/análise , Imidazóis/análise , Tetrazóis/análise , Anti-Hipertensivos/sangue , Anti-Hipertensivos/urina , Compostos de Bifenilo/sangue , Compostos de Bifenilo/urina , Cromatografia Líquida de Alta Pressão , Humanos , Imidazóis/sangue , Imidazóis/urina , Losartan , Receptor Tipo 1 de Angiotensina , Receptor Tipo 2 de Angiotensina , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Espectrometria de Fluorescência , Tetrazóis/sangue , Tetrazóis/urinaRESUMO
We investigated the tolerability and angiotensin II antagonist activity of oral DuP 532 in healthy male subjects. DuP 532 (1 to 200 mg) was well tolerated, with no effect on blood pressure or heart rate. Compared with losartan (100 mg), DuP 532 (200 mg) was a weak antagonist of pressor responses to intravenous angiotensin II. Maximum inhibition of diastolic pressor response was 86% (95% confidence interval [CI], 84%, 88%) approximately 4.6 hours after losartan and 48% (95% CI, 38%, 56%) 8.7 hours after DuP 532. Twenty-four hours after dosing, inhibition by losartan and DuP 532 was similar (40% to 45%). DUP 532 is extensively bound in human plasma, with an in vitro free fraction of 0.06. Although DuP 532 and EXP3174 (losartan's active metabolite) have similar AT1-receptor potency, and plasma concentrations of DuP 532 were much greater than losartan/EXP3174, the level of antagonism was much less for DuP 532. These results indicate that multiple factors determine the in vivo potency of angiotensin II antagonists, including affinity for and distribution to the receptor as modulated by plasma binding.
Assuntos
Angiotensina II/metabolismo , Antagonistas de Receptores de Angiotensina , Compostos de Bifenilo/farmacologia , Imidazóis/farmacologia , Tetrazóis/farmacologia , Adulto , Compostos de Bifenilo/administração & dosagem , Pressão Sanguínea/efeitos dos fármacos , Método Duplo-Cego , Frequência Cardíaca/efeitos dos fármacos , Humanos , Imidazóis/administração & dosagem , Losartan , Masculino , Renina/sangue , Tetrazóis/administração & dosagemRESUMO
Losartan, a selective angiotensin II (AT1) receptor antagonist for hypertension, is metabolized to an active carboxylic acid metabolite, E-3174, which has a longer half-life. To investigate the effects of induction of cytochrome P450 on the metabolism of losartan, we evaluated the effects of phenobarbital on the plasma profiles of losartan and E-3174 in 15 healthy male subjects. Ten subjects received a single 100 mg oral dose of losartan before and during phenobarbital administration (100 mg/day for 16 days), and five subjects received losartan before and during placebo. Urinary excretion of 6-beta-hydroxycortisol (relative to 17-hydroxycorticosteroids) was measured as an endogenous marker of cytochrome P450 induction. The geometric mean area under the plasma concentration-time curve ratios (with/without phenobarbital and 90% confidence intervals) for losartan and its metabolite (E-3174) were 0.795 (0.723, 0.875) and 0.799 (0.778, 0.820), respectively, indicating that phenobarbital treatment significantly but to a clinically minor extent reduced plasma concentrations of losartan and E-3174 (p<0.01). Half-life values of losartan and E-3174 were unchanged. The ratio of 6-beta-hydroxycortisol to 17-hydroxycorticosteroids doubled in the phenobarbital group (p < 0.001) and did not change appreciably in the placebo group.
Assuntos
Anti-Hipertensivos/farmacocinética , Compostos de Bifenilo/farmacocinética , Imidazóis/sangue , Imidazóis/farmacocinética , Fenobarbital/farmacologia , Tetrazóis/sangue , Tetrazóis/farmacocinética , Adulto , Anticonvulsivantes/farmacologia , Anti-Hipertensivos/sangue , Compostos de Bifenilo/sangue , Citocromo P-450 CYP3A , Sistema Enzimático do Citocromo P-450/biossíntese , Indução Enzimática/efeitos dos fármacos , Humanos , Hidrocortisona/análogos & derivados , Hidrocortisona/urina , Hipnóticos e Sedativos/farmacologia , Losartan , Masculino , Oxigenases de Função Mista/biossíntese , Valores de Referência , Método Simples-CegoRESUMO
To support the use of a combination of losartan, a highly specific and selective AT1 angiotensin II receptor antagonist, and hydrochlorothiazide for treatment of hypertension, a pharmacokinetic drug interaction study was conducted. In this open-label, randomized, three-period, crossover study, patients with mild to moderate hypertension received a 12.5-mg tablet of hydrochlorothiazide, a 50-mg losartan tablet, or a combination tablet of 12.5 mg of hydrochlorothiazide and 50 mg of losartan for 7 days. Twelve patients (age range, 35-55 years; mean age, 44 years) were allocated to treatment. Drug interactions were evaluated by comparing the 24-hour area under the concentration-time curve (AUC24) for losartan and its active metabolite, E-3174, when losartan (50 mg) was given alone or in combination with 12.5 mg hydrochlorothiazide. The urinary recovery over the 24-hour period of hydrochlorothiazide was compared for hydrochlorothiazide (12.5 mg) given alone or in combination with 50 mg losartan. A clinically significant interaction was defined as a treatment difference of more than 35%. There was no evidence of a clinically significant effect of hydrochlorothiazide on the pharmacokinetics of losartan or E-3174, as the geometric mean AUC24 ratio (90% confidence interval [CI]) was 1.02 (0.95, 1.09) for losartan and 1.02 (0.96, 1.09) for E-3174. Based on urinary recovery over a 24-hour period of hydrochlorothiazide, losartan did not affect the pharmacokinetics of hydrochlorothiazide, as the geometric mean ratio of urinary hydrochlorothiazide recovery (90% CI) was 0.898 (0.79, 1.20). There was a minor (17%) decrease in the AUC24 of hydrochlorothiazide after administration of the combination tablet. Coadministration of hydrochlorothiazide and losartan was well tolerated.